Gastrointestinal effects represent the most frequently reported adverse reactions, occurring in a substantial proportion of patients, particularly during treatment initiation and dose escalation: Nausea (very common, affecting more than 1 in 10 people) typically peaks during the first few weeks and often diminishes with continued treatment [1] [2] Diarrhoea (very common, affecting more than 1 in 10 people) Vomiting (common, affecting up to 1 in 10 people) Abdominal pain, constipation, and dyspepsia occur with variable frequency Reduced appetite is an expected pharmacological effect contributing to weight loss but may occasionally be excessive These gastrointestinal symptoms usually improve over time as the body adjusts to the medication
In addition, studies show that complications of MASLD are not limited to hepatobiliary sequelae but also include CVD, chronic kidney disease, and an enhanced tendency to cancer (2325)
Semaglutide is typically prescribed for adults with type 2 diabetes who need help managing their blood sugar levels
As agents such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) continue to deliver robust A1C reduction and double-digit weight loss, clinicians must balance metabolic gains with careful risk assessment
A 2023 study by Azuri et al showed 17.8% total body weight loss for tirzepatide vs
In controlled lighting studies involving rodents subjected to constant illumination (a stressor that disrupts circadian patterns), intermittent Epithalon treatment normalized melatonin and cortisol rhythms, partially preserving typical daynight physiological cycles [2][4][5]
-1.jpg&w=1200&q=75)
